Capricor Therapeutics: CAP-1002 HOPE-3 Program Update
by: Parent Project Muscular Dystrophy
PPMD and Capricor Therapeutics held a community webinar on October 25, 2023 to provide an overview of the latest regulatory developments for Capricor’s ongoing HOPE-3 Phase 3 study of CAP-1002, the company’s cell therapy. Capricor’s CEO Linda Marbán, Ph.D. and Vice President of Clinical Operations Mark Awadalla shared information about CAP-1002’s clinical data trajectory and answered questions from the community.
by: Parent Project Muscular Dystrophy
